Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ablynx has received an undisclosed milestone payment from Novartis for an exclusive research license in one of the programs that is a component of their ongoing research and development alliance.
Subscribe to our email newsletter
Novartis and Ablynx are collaborating to discover and develop therapeutic Nanobodies for a range of disease areas, against a number of targets that are difficult to address with conventional antibodies and their fragments. The alliance was entered into in December 2005, and extended in December 2007 for a further year.
Edwin Moses, CEO and chairman of Ablynx, said: “We are pleased to see this first Nanobody program from our collaboration with Novartis advancing to the next stage and to make progress in what is an important alliance for Ablynx.”